Oncology Drug Value Tools From NCCN, ASCO To Get Real-World Testing
This article was originally published in The Pink Sheet Daily
Officials from oncology professional organizations discuss next steps in the development of their frameworks for valuing oncology drugs.
You may also be interested in...
ASCO's chief medical officer Richard Schilsky discusses innovative clinical trial designs in oncology, challenges facing developers of cancer combination therapies and future developments for the society's value frameworks.
'Patients are ready and willing to have conversations' about trade-offs, National Health Council's Perfetto says.
The most detailed US reporting requirements regarding prescription drug costs and coverage will target medicines reimbursed under the retail pharmacy benefit.